BIZM closed over the counter Friday at $3.18 a share. It’s the
developer of a version of the hand-held Star Trek diagnostic device discussed today in my companion post.
My 20-day
performance chart hints at an uptrend in the stock, barring any unexpected
negative announcement about BIZM, Biozoom, Dr. Jansen, or the device.
Given nothing but good news, the stock’s potential for price
appreciation appears to be enormous.
We'll see. Never forget: Every kind of savings and investment depends, like all of life, on the unknowable future.
No comments:
Post a Comment